GoodRx price target raised to $8 from $6 at RBC Capital

RBC Capital analyst Sean Dodge raised the firm’s price target on GoodRx to $8 from $6 and keeps a Sector Perform rating on the shares after its Q2 earnings topped estimates. The company’s softer revenue outlook reflects both a rationalization of unprofitable areas as well as a shift in focus toward profitability and sustainable growth, largely in the form of tighter and more-integrated partnerships, though 2023 should still be considered a “reset year”, the analyst tells investors in a research note.